Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer

Area of Science:

• Oncology
• Cellular Biology

Background:

• Endocrine therapy is standard for ER-positive, HER2-negative breast cancer, but tumor progression and recurrence remain challenges.
• Residual tumor cells can enter a dormant state but may reactivate, leading to relapse and acquired therapy resistance.
• Autophagy, a cellular stress response, is implicated in the survival and reactivation of these dormant tumor cells.

Purpose of the Study:

• To review the relationship between endocrine therapies and autophagy in ER-positive breast cancer.
• To explore the diverse roles of autophagy in response to endocrine treatments.
• To investigate targeting autophagy as an adjuvant therapy alongside endocrine treatments.

Main Methods:

• Literature review of studies investigating endocrine therapy and autophagy in breast cancer.
• Analysis of the functional roles of autophagy in therapy-induced cellular adaptation and survival.
• Exploration of potential therapeutic strategies involving autophagy modulation.

Main Results:

• Autophagy can be a double-edged sword in cancer therapy, sometimes protecting tumor cells and sometimes mediating cell death.
• The regulation of autophagy is critical in determining its effect on tumor cell survival and dormancy.
• Understanding autophagy's role offers insights into overcoming endocrine therapy resistance.

Conclusions:

• Autophagy is a key cellular mechanism influencing the response to endocrine therapy in breast cancer.
• Modulating autophagy presents a promising avenue for novel adjuvant therapeutic strategies.
• Targeting autophagy could enhance the efficacy of endocrine treatments and prevent disease recurrence.